Of clinical relevance, spatially resolved ligand-receptor analysis revealed tumor cells at the stromal interface preferentially expressing fibronectin-binding integrins (ITGA5/ITGB1) 80, and targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade 81. Here, ITGB1 is linked to colorectal cancer.